AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04370379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2mg, q4week (3 injections) followed by q8week
Study NCT02337985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02337985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02337985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02337985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02337985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02337985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02337985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02337985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Description: Given IV
Study NCT01571453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 10 mg/day
Study NCT01571453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine extended release
Description: 150 mg/day
Study NCT04971941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Vibe
Description: Use of Dental Vibe during dental anesthesia intervention
Study NCT04971941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Vibe
Description: Use of Dental Vibe during dental anesthesia intervention
Study NCT00129961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Study NCT00129961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine or tacrolimus
Study NCT00849862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 750 mg Tablet
Study NCT00849862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 750 mg Tablet
Study NCT02373514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 gr paracetamol in 100 ml saline with rapid infusion
Study NCT02373514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 50 mg dexketoprofen in 100 ml saline with rapid infusion
Study NCT00169221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa (Gefitinib)
Description: postoperative chemoradiotherapy with cisplatin + gefitinib
Study NCT00169221 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy with cisplatin
Description: postoperative chemoradiotherapy with cisplatin
Study NCT03871660 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre Pro
Description: Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
Study NCT00129467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is > 10 at day 18, the dose may be increased to 15 mg bid.
Study NCT00129467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention.
Study NCT00129467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selective Serotonin Uptake Inhibitor (SSRI)
Description: Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion
Study NCT00129467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Uptake Inhibitor (SSRI)
Description: Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion
Study NCT00778895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' influenza vaccine GSK1557482A
Description: one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
Study NCT00778895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip
Description: one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
Study NCT02967601 — intervention group
Intervention type: BEHAVIORAL
Intervention: STAI (State Trait Anxiety Inventory) questionaire
Description: Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
Study NCT00908726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
Study NCT00908726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
Study NCT00949325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus plus liposomal doxorubicin
Description: Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
Study NCT00574054 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared
Description: Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
Study NCT01271920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Study NCT01271920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01510379 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reletex
Description: Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
Study NCT01510379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reletex
Description: Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
Study NCT01510379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV ondansetron 4 mg q 6 hours for a total of 4 doses
Study NCT01510379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ondansetron 4 mg q 6 hours for a total of 4 doses
Study NCT00710242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF01
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Study NCT00710242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
Study NCT01634295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 5/40mg
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Study NCT01634295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 5/80mg
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks.
Study NCT04627233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
Study NCT03349840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec U100
Description: Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
Study NCT03349840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
Study NCT03699501 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: * A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)
Study NCT03699501 — intervention group
Intervention type: PROCEDURE
Intervention: Oral examination
Description: * An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index
Study NCT04232436 — intervention group
Intervention type: OTHER
Intervention: Survival at discharge
Description: Survival at discharge
Study NCT04232436 — intervention group
Intervention type: OTHER
Intervention: Survival without severe morbidity
Description: Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
Study NCT04365933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets
Study NCT04365933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Oral tablets
Study NCT01723475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY2010112
Description: Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
Study NCT03699501 — intervention group
Intervention type: OTHER
Intervention: questionnaires (test-retest)
Description: SCOOHP and SOHP questionnaires
Study NCT00735163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced model predictive control algorithm (eMPC)
Description: eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
Study NCT01723475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY2010112
Description: Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
Study NCT01942421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultivated mucosal epithelial transplantation
Description: cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
Study NCT01634295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 2.5mg
Description: * S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks.
Study NCT02322905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy
Description: 8 sessions of ERT
Study NCT02918812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracervical lidocaine
Description: Intracervical lidocaine injected at four different points
Study NCT02918812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Diclofenac
Description: Intramuscular Diclofenac 30 mins before HSG
Study NCT03366207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
Study NCT01634295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 5mg
Description: * S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks.
Study NCT04385537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PECAN
Description: Raw pecan halves without other changes to their habitual diet.
Study NCT00196326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1011
Description: Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
Study NCT04365933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha2a
Description: Subcutaneous
Study NCT04226040 — intervention group
Intervention type: BEHAVIORAL
Intervention: DOW and illness perception
Description: Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
Study NCT01242566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: orally 150-200 mg/m2/day for 5 consecutive days every 4 week
Study NCT04435990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10,000 MM09
Description: Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
Study NCT04435990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30,000 MM09
Description: Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
Study NCT04435990 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: The same solution and presentation as the active treatment, but without active ingredients.
Study NCT02186717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Patients will be asked to chew gum three times a day for 30 minutes each time
Study NCT01510379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV promethazine 25 mg q 6 hours prn
Study NCT01510379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV promethazine 25 mg q 6 hours prn
Study NCT01510379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Elixir promethazine 25 mg q 6 hours prn after discharge
Study NCT01510379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elixir promethazine 25 mg q 6 hours prn after discharge
Study NCT03166215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-935
Description: TAK-935 tablets.
Study NCT03166215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 tablets.
Study NCT03166215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching tablets.
Study NCT01662713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI
Description: Imaging of skin
Study NCT04491760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
Study NCT03024723 — intervention group
Intervention type: DEVICE
Intervention: nasal mask CPAP
Description: CPAP and ventilation administered via nasal mask
Study NCT01543789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal mesh placement
Description: Mesh placement inside the peritoneal cavity.
Study NCT01543789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preperitoneal mesh placement
Description: Mesh placement between peritoneum and muscle layer.
Study NCT02030990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: 0.01% applied to cornea with a sponge during PRK
Study NCT02030990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 1% topical ocular steroid
Description: topical steroid drops applied to the cornea after PRK
Study NCT02030990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone 1% topical ocular steroid
Description: topical steroid drops applied to the cornea after PRK
Study NCT00892138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: 7 week course modeled on MBSR according to Kabat-Zinn
Study NCT03408210 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0.